Sedia™ HIV-1 LAg-Avidity EIA

CDC Approved Sedia™ HIV-1 LAg-Avidity EIA to Determine Recency of Infection and Estimate HIV-1 Incidence


The Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA is an in vitro single well quantitative limiting antigen avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term.  The assay is intended for use with liquid serum or plasma specimens.  Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG. 



The Sedia™ HIV-1 LAg-Avidity EIA uses U.S. Centers for Disease Control and Prevention (CDC) developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and recognizing those high-incidence populations so that prevention research, vaccine trials, and resources are most appropriately utilized.  

The HIV-1 LAg-Avidity EIA was first commercialized by Sedia in cooperation with the CDC.  Sedia is a supplier for CDC HIV Incidence Studies using the HIV-1 LAg-Avidity EIA.

Customers wishing to test dried blood spot specimens instead of liquid serum or plasma specimens, should purchase Cat. No. 1003 Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots

Ordering Information

Cat. No. 1002

Sedia™ HIV-1 LAg-Avidity EIA, 192 Tests

Cat. No. 1003

Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots, 192 Tests

For Research Use Only.  Not for Use in Diagnostic Procedures.

U.S. CDC Approved

Each Sedia™ HIV-1 LAg-Avidity EIA lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.

Certification of CDC testing and approval is provided with each assay kit.

Use of Sedia™ HIV-1 LAg-Avidity EIA in the U.S.

The  Sedia™ HIV-1 LAg-Avidity EIA is for Research Use Only and Not for Use in Diagnostic Procedures. Users of the Sedia™ HIV-1 LAg-Avidity EIA based in the U.S. are required to complete and submit a Certification Regarding Research Use (download here) prior to shipment of the product certifying that use of the product will be used for research use only in compliance with FDA regulations.

Independent Evaluation of Sedia™ HIV-1 LAg-Avidity EIA by the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

The  Sedia™ HIV-1 LAg-Avidity EIA has been evaluated by CEPHIA under a grant funded by the Bill and Melinda Gates Foundation, the results of which have been published in the peer-reviewed journal AIDS (available here).   Overall, the Sedia™ HIV-1 LAg-Avidity EIA displayed the lowest False Recency Rate of any HIV incidence assay evaluated.   Many laboratories are now using the Sedia™ HIV-1 LAg-Avidity EIA in conjunction with viral load testing to further reduce this false incidence rate.







| Home | About Us | Contact Us | Jobs | Privacy Policy | Terms of Use | Search | Site Map |     © Copyright 2016 - Sedia Biosciences Corporation
Top